4-1BB agonism: adding the accelerator to cancer immunotherapy

Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework

(2015) Rienk Offringa et al.   CANCER CELL

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors

(2015) Cariad Chester et al.   CURRENT OPINION IN IMMUNOLOGY

Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma

(2015) Fei Chen et al.   MEDICAL SCIENCE MONITOR

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

(2015) Todd Bartkowiak et al.   Frontiers in Oncology

Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer

(2014) Vanessa Gauttier et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting CD137 enhances the efficacy of cetuximab

(2014) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients

(2013) R. M. Srivastava et al.   CLINICAL CANCER RESEARCH

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

(2013) Michael A. Curran et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ectopic CD137 expression facilitates the escape of Hodgkin and Reed-Sternberg cells from immunosurveillance

(2013) Wan Lu Pang et al.   OncoImmunology

Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb

(2013) Aizea Morales-Kastresana et al.   Journal for ImmunoTherapy of Cancer

CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas

(2012) Matthew W. Anderson et al.   AMERICAN JOURNAL OF PATHOLOGY

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer

(2012) Kuang Youlin et al.   Clinical & Developmental Immunology

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

A Converse 4-1BB and CD40 Ligand Expression Pattern Delineates Activated Regulatory T Cells (Treg) and Conventional T Cells Enabling Direct Isolation of Alloantigen-Reactive Natural Foxp3+ Treg

(2012) A. Schoenbrunn et al.   JOURNAL OF IMMUNOLOGY

4-1BB signaling beyond T cells

(2011) Dass S Vinay et al.   Cellular & Molecular Immunology

T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy

(2011) Laura M. Snell et al.   IMMUNOLOGICAL REVIEWS

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

(2009) R. Houot et al.   BLOOD

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

(2009) Chao Wang et al.   IMMUNOLOGICAL REVIEWS